Business Context and Reporting Period
This Form 8-K is a current report filed by TRxADE HEALTH, Inc. (Ticker: MEDS) on July 14, 2023. The filing discloses the entry into an Amended and Restated Agreement and Plan of Merger with Superlatus, Inc., a U.S.-based holding company for food products and distribution. This agreement amends a merger originally announced on June 30, 2023.
Key Financial Metrics and Transaction Terms
The filing details the financial structure of the proposed merger rather than reporting standard operational financial metrics (revenue, profit, cash flow) for the period.
- Merger Consideration: Superlatus shareholders will receive an aggregate of 30,821,941 shares of TRxADE stock valued at $7.30 per share.
- Share Composition: The consideration consists of:
- 136,441 shares of TRxADE common stock (representing 19.99% of post-merger outstanding shares).
- 306,855 shares of TRxADE Series B Preferred Stock (convertible at a 100-to-1 ratio).
- Shareholder Rights: Existing TRxADE shareholders will receive non-transferrable rights to receive one share of common stock at no cost for every seven shares held as of the record date.
Material Changes Versus Prior Period
The primary material change is the amendment to the Original Merger Agreement dated June 30, 2023. Key modifications include:
- Revised Consideration: Adjustment of the merger consideration payable to Superlatus shareholders.
- New Rights Issuance: Addition of the issuance of non-transferrable rights to existing TRxADE shareholders.
- Timeline Extension: Extension of the deadline for delivering ancillary documents (including Shareholder Support and Lock-Up Agreements) to within 10 days of the A&R Merger Agreement execution.
Guidance, Outlook, Risks, and Contingencies
The filing contains forward-looking statements regarding the expected success of the combined business but provides no specific financial guidance or revenue projections.
Risks and Contingencies
- Merger Completion: Risks that conditions to closing are not satisfied, or the merger is terminated or abandoned.
- Regulatory and Legal: Potential legal proceedings related to the merger documents and intellectual property claims.
- Operational: Difficulties in employee retention and integration of the combined business.
- Financial: Risks related to the ability to raise future funding and maintain Nasdaq listing status.
- Lock-Up Restrictions: Certain equity holders must enter into lock-up agreements, and MEDS Rights cannot be exercised until shares are registered or confirmed exempt, with a one-year transfer restriction post-closing.
Investor Verification Checklist
- Verify the final terms of the Amended and Restated Agreement and Plan of Merger (Exhibit 2.1) to confirm the exact share counts and conversion ratios.
- Confirm the MEDS Rights Record Date to determine eligibility for the free share issuance.
- Review the Superlatus Shareholder Support Agreement and Lock-Up Agreements for restrictions on share sales post-merger.
- Assess the status of regulatory approvals and shareholder votes required to consummate the merger.
- Monitor the company's ability to maintain its Nasdaq listing during the merger process.